Interleukin-6 (IL-6) and C-reactive protein (CRP) concentration prior to total nephrectomy are prognostic factors in localized renal cell carcinoma (RCC)  by Hrab, Michał et al.
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 304–309
Available  online  at  www.sciencedirect.com
jo ur nal home p ag e: ht tp : / /www.e lsev ier .com/ locate / rpor
Original research article
Interleukin-6  (IL-6)  and  C-reactive  protein  (CRP)
concentration prior  to  total  nephrectomy  are
prognostic factors  in localized  renal  cell  carcinoma
(RCC)
Michał Hraba, Karolina Olek-Hrabb, Andrzej Antczaka, Zbigniew Kwiasa,
Tomasz Milecki c,∗
a Department and Clinic of Urology and Urologic Oncology, University of Medical Sciences, 3 Szwajcarska St,
61-285 Poznan, Poland
b Department and Clinic of Dermatology, University of Medical Sciences, 49 Przybyszewskiego St, 61-355 Poznan,
Poland
c Scientiﬁc Society of Urology, University of Medical Sciences, Poznan, Poland
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 18 February 2013
Accepted 13 June 2013
Keywords:
Renal cell carcinoma
Interleukin-6
C-reactive protein
Prognostic factors
Nephrectomy
a  b  s  t  r  a  c  t
Background: Radical nephrectomy is the gold standard for treatment of renal cell carcinoma
(RCC), but even for localized disease the survival rates are still unsatisfactory. Identiﬁcation
of  prognostic factorsl is the basis for future treatment strategies for an individual patient.
Aim:  The aim of our study was to assess the usefulness of the concentration of IL-6 and CRP
as  prognostic factors in patients after nephrectomy due to localized RCC.
Materials and methods: Our prospective study included 89 patients (55 men  and 34 women)
who had been surgically treated for RCC. The examined group included patients with local-
ized advanced disease (from T1 to T3) with no metastases in lymph nodes (N0), and with
no  distant metastases (M0). All patients had blood samples drawn three times during the
study (one day before surgery, six days after surgery and 6 months after surgery) to evaluate
the  concentration of CRP and IL-6. In each patient RCC of the kidney was removed during
radical nephrectomy. Statistical analysis was conducted using statistica v.7.0.
Results: Statistically signiﬁcant relationships were found between the concentration of CRP
before the operation and OS (p = 0.0001). CRP concentration at baseline was statistically sig-
niﬁcantly correlated with CSS (p = 0.0004). The level of IL-6 assessed before the surgery was
signiﬁcantly correlated with survival times such as OS (p = 0.0096) and CSS (p = 0.0002). The
concentration of IL-6 and CRP measured 6 days after surgery and 6 months after surgerywere  not statistically signiﬁcantly correlated with survival times.
Conclusions: Results of our study showed that elevated levels of IL-6 and CRP in peripheral
blood before surgery of RC
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Table 1 – Blood tests results before surgery, after 6 days and after 6 months for 89 patients with RCC after radical
nephrectomy.
Variables Baseline (prior surgery) After 6 days After 6 months Signiﬁcance level
N 89 89 69
WBC 7.48 (3.15–18.43) 8.38 (3.2–15.4) 7.48 (3.55–30.8) 0.00294
RBC 4.57 (3.13–5.78) 3.94 (2.77–4.91) 4.70 (2.56–7.62) <0.0001
HGB 8.29 (7.1–10.7) 7.20 (7.5–12.4) 8.65 (7.6–12.4) <0.0001
PLT 259.60 ± 103.78 (78.0–651.0) 313.39 ± 103.48 (121.0–583.0) 242.16 (119.0–562.0) <0.0001
LDH 346.36 (169.0–846.0) 435.42 (208.0–895.0) 34,280 (228.0–597.0) <0.0001
FE 17.48 (3.5–39.0) 7.66 (2.0–21.4) 17.64 (3.1–44.5) <0.0001
CHOL 5.24 (3.2–8.8) 4.88 (3.0–9.4) 5.84 (3.7–8.9) <0.0001
331.7) 105.71 (3.2–242.1) <0.0001
301.6) 6.53 (0.2–50.3) <0.0001
35.8) 3.59 (0.0–63.68) <0.0001
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Table 2 – Clinical and pathological characteristic of 89
patients with RCC after radical nephrectomy.
Parameters Value
Number of patients
N = 89(100%)
Gender
Male 55(62)
Female 34(38)
Tumor stage
pT1 47(53)
pT2 23(26)
pT3 19(21)
Tumor grade
G1 27(30)
G2 47(53)
G3 15(17)
Mean age 60.8
Survival
Alived 74(83)
Deceased 15(17)Cre 84.58 (48.2–216.5) 110.72 (55.3–
CRP 19.13 (0.5–178.1) 61.40 (11.4–
IL-6 11.63 (0.0–291.8) 17.47 (0.0–1
.  Background
enal cell carcinoma (RCC) accounts for about 3–4% of malig-
ant neoplasms in adults. In Poland, in 2008, RCC was
iagnosed in 2469 men  and 1695 women. The number of
eaths caused by the disease amounted to 1574 in men  and
89 in women.1 Radical nephrectomy is the gold standard for
reatment of RCC, but even for localized disease the survival
ates are still unsatisfactory. Identiﬁcation of good predic-
ors of survival is the basis for future treatment strategies
or an individual patient. Prognostic factors are universally
tilized in the management of many  cancers and take an
mportant role in their treatment.2,3 Prognostic factors can
llow in the future to establish more  efﬁcient supplementary
ethods of therapy for RCC. Generally, prognostic factors in
CC are divided into anatomical, histological and molecular.
any  molecular factors have been examined in terms of their
linical usefulness in the course of RCC. Among them were
arbonic anhydrase 9 (CA9), vascular endothelial growth factor
VEGF), hypoxia-inducible factor (HIF), p53 protein, E-cadherin
nd many  others. Unfortunately, none of them has been con-
rmed to be a reliable prognostic factor and they have not been
sed in daily clinical practice.4–6 The usefulness of other pro-
nostic factors in RCC with potential clinical usability, such as
L-6 and CRP, is yet to be conﬁrmed.
.  Aim
he aim of our study was to assess the usefulness of the con-
entration of IL-6 and CRP as prognostic factors in patients
fter nephrectomy due to localized RCC.
.  Materials  and  methods
9 patients (55 men  and 34 women) aged from 30 to 81 years
mean age 60.08 ± 9.99 years) were included into this prospec-
ive study. All patients had been surgically treated for RCC in
he Clinic of Urology and Urologic Oncology of the Poznan Uni-
ersity of Medical Sciences from 2004 to 2005 year. All patients
ith primary renal tumor were diagnosed by ultrasono-
raphic (US) examination and computer tomography (CT). The
xamined group included patients with localized advanced
isease (from cT1 to cT3) without metastases in lymphCancer related 11(12)
Non-cancer related 4(5)
nodes (cN0) and no distant metastases (M0). All patients had
blood samples drawn three times during the study: one day
before surgery as baseline, six days after surgery, and the
last one six, months after surgery (Table 1). The patients’
performance status according to the Eastern Cooperative
Oncology Group (ECOG) was 0 or 1 and none of them suf-
fered from chronic inﬂammatory disease nor had undergone
prior surgery hemodialysis, blood transfusion, radiotherapy,
chemotherapy, and immunotherapy. In each case, the kidney
removed during nephrectomy was histopathologically exam-
ined in the Department of Histopathology of the General
Municipal Hospital in Poznan. To assess pathological tumor
stage, the TNM classiﬁcation from 2002 was used. All patients
with histologically conﬁrmed metastases to lymph nodes
and/or pT4 stage were excluded from the study. Patient’s clin-
ical and pathological characteristics are presented in Table 2.
All patients were followed after the operation at the Urol-
ogy Clinic in Poznan according to the following schema: ﬁrst
visit after surgery was at 1 month, then at 3-month intervals
up to one year, and thereafter, at 6-month intervals up to the
end of follow-up. During each visit, the following examina-
tions were conducted: general examination, US of abdomen
d radiotherapy 1 8 ( 2 0 1 3 ) 304–309
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Fig. 1 – Kaplan–Meier survival probability analysis in
relation to the concentration of interleukin-6.
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Fig. 2 – Kaplan–Meier survival probability analysis in
relation to the concentration of C-reactive protein.
Cancer specific survival (CSS)
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Fig. 3 – Probabilities of carcinoma-speciﬁc survival for306  reports of practical oncology an
and/or CT, chest X-ray (once per year) and additional exami-
nations in any case of suspected disease progression. CRP was
measured using the rocket immunoelectrophoresis method
with the established reference value of up to 5 mg/l. Quan-
titative analysis of human IL-6 was conducted with the use of
the sandwich ELISA technique (Enzyme-Linked Immunosor-
bent Assay) with a complete analysis set by R&D Systems
with the method sensitivity of 0.70 pg/ml. The test procedure
was conducted according to the manufacturer’s recommenda-
tions, and the results were analyzed using KC Junior software
by Bio-Tek.
Statistical analysis was conducted using Statistica version
7.0 where the following tests were applied: Wilcoxon, Fried-
man and ANOVA tests. Additionally for survival times survival,
curves were generated using the Kaplan–Meier method. The
study was approved by the Bioethics Commission at the Uni-
versity of Medical Sciences, Poznan´.
4.  Results
During the follow-up, 4 patients died for reasons unrelated
to cancer: myocardial infarction (n = 3), cerebral stroke (n = 1).
On the other hand, death caused by development of RCC
was observed for 11 patients. Statistically signiﬁcant relation-
ships were found between the higher concentration of CRP
at baseline (before the operation) and shorter survival time
(p = 0.0001). The higher level of IL-6 measured before the oper-
ation correlated with worst survival times (p = 0.0096), too. An
analysis of IL-6 showed higher mean values in the group of
patients with death related to RCC (23.8 units) in compari-
son with the group of living patients (9.2 units). In the group
of patients who died due to RCC, mean CRP concentration at
baseline was 49.7 units. On the other hand, mean CRP level in
the group of living patients was 12.9 units. However, 3 patients
in the group of 52 patients with initially normal results of
CRP test died. The examination of IL-6 concentration before
the operation showed that 9 (38%) patients of the group of 24
patients with an elevated level of IL-6 died, while in the group
of 74 patients with normal results only 6 (9%) patients died.
Longer OS time was demonstrated in the group of patients
with RCC, in whom the CRP concentration before the begin-
ning of therapy was normal, in comparison to the group of
patients with an increased CRP concentration (log-rank test
p = 0.001). Longer survival time was noted in the patients in
whom the interleukin-6 level before the surgery was normal
when compared to the group with initially elevated IL-6 level
(log-rank test, p = 0.001) (Figs. 1 and 2).
We analyzed also CSS depending on CRP and IL-6. Statis-
tically signiﬁcant correlations were found for both. A longer
survival time was observed in the patients in whom CRP lev-
els before the operation were normal when compared to the
patients with an initially increased levels of the protein (log-
rank test, p = 0.0004) (Fig. 3). A longer CSS time was found also
in the patients with a normal initial IL-6 concentration as com-
pared to the patients with IL-6 concentration above normal
(Fig. 4).
In our analysis, there were no correlation between concen-
tration of IL6 and CRP after surgery (6 days after surgery and 6
months after surgery) in terms of CSS and OS.
patients with localized RCC according to concentration of
CRP (normal level versus higher level) prior to radical
nephrectomy.
reports of practical oncology and radio
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Fig. 4 – Probability of carcinoma speciﬁc survival for
patients with localized RCC (normal level vs. abnormal
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in RCC. Blay et al. conﬁrmed the role of IL-6 in RCC. Theyevel) according to IL-6 concentration prior radical
ephrectomy.
.  Discussion
CC derived from epithelium of renal tubules accounts for
bout 90% of primary renal carcinomas in adults.7 It is a het-
rogeneous cancer and, in addition, the one with complex
iology which does not allow to follow clearly the course of
he disease; therefore, prognostication in many  patients is
ery difﬁcult. In most locally advanced tumors, recovery after
adical nephrectomy or partial tumor removal in the case of
mall tumors, can be expected. Unfortunately, one has to be
ware that studies demonstrate that distant metastases may
evelop in about 30% of these patients.8,9 Ongoing research
ttempts to identify factors that could help in a more  precise
etermination of the course of RCC and enable to distinguish
he groups of patients for whom complementary treatment
hould be offered. Therefore, maybe in a future, the ability
o recognize the risk groups for the disease progression will
llow to administer treatment adequate to the degree of dis-
ase development. At present, prognostic factors in locally
dvanced RCC can be divided into anatomical, histological,
linical and molecular. Clinical prognostic factors for OS in
CC are extensively discussed in the literature and come
nder review in most scientiﬁc papers.10 In most papers, the
ssessment of acute phase parameters in prognostication of
CC is limited to CRP and proinﬂammatory cytokines. In our
resent study, we  focused on searching for prognostic fac-
ors that can help in prognosis in patients after nephrectomy
ue to locally advanced RCC. The study included results of
ssessment of CRP and IL-6 concentrations one day before
he surgery at baseline. At present CRP is considered a sensi-
ive indicator that suggests the presence of an inﬂammatory
tate and reﬂects its intensity. An increased CRP concen-
ration is an undeniable evidence of a disease process. CRP
onitoring seems to be a good diagnostic test of a disease
rocess.11,12 In the last few years, assessment of CRP con-
entration has been carried out in numerous clinical studies
n many  diseases of inﬂammatory origin. The following dis-
ase entities can be named here: bone and joint inﬂammation,therapy 1 8 ( 2 0 1 3 ) 304–309 307
rheumatoid arthritis, psoriasis vulgaris, arthropathic psoria-
sis, endocarditis, Alzheimer’s disease and eye diseases where
increased concentration of CRP is observed in intraocular
inﬂammation, and in patients with cellulitis, keratitis and
uveitis.13 Increase CRP concentration has also been observed
in the course of the neoplastic process. The available liter-
ature describes cases of an increased CRP concentration in
such cancers as: breast, lung, ovarian or esophageal.14–19 In
our study, we assessed prognostic factors (CRP and IL-6), in
particular time periods in RCC patients. Distinctly higher lev-
els of CRP and IL-6 were observed before the operation. Our
study demonstrated that the lower CRP concentration before
the operation was correlated with the longer survival times
(OS, CSS) of RCC patients. In addition, the analysis conducted
in the study showed that a higher IL-6 level before surgery
was associated with shorter survival times (OS, CSS), too. So
far, many  studies have been conducted on RCC survival time.
Lamb et al. showed on a group of 100 patients with RCC the
inﬂuence of CRP concentration before the operation on the
course of the disease and on CSS patients with RCC. They
demonstrated that in patients with an initial CRP level above
10 mg/dl, CSS was 71 months versus 96 months in the group
of patients with CRP below 10 mg/dl (p = 0.001).20 The same
research team, two years later, conducted another analysis
on a group of 60 patients with RCC. A relationship between
CRP, IL-6, and expression of cyclooxygenase (COX-2), concen-
tration of CD4+ and CD8+, T-lymphocytes and probability of
CSS was analyzed. The association between CRP concentra-
tion and CSS and probability of recurrence-free survival was
demonstrated.21 Masuda et al. in their study on a group of 111
patients found that CRP concentration is a negative progno-
stic factor in RCC dependent on TNM and Robson staging.22
Komai et al. conducted research on a group of 101 patients sub-
jected to radical nephrectomy due to RCC (pT1-3N0M0). They
assessed CRP concentration as a prognostic factor in RCC. An
elevated CRP level (>0.5 mg/dl) was observed in 26 patients, of
whom 12 (46%) and 3 of the other group of 75 patients died
due to RCC. They demonstrated signiﬁcantly lower survival
in the group of patients with an increased CRP level than in
the normal concentration of the protein (p < 0.001).23 Fujikawa
et al. in their study suggested that a reduction in CRP level in
response to cytoreductive nephrectomy and complementary
immunotherapy predicts better prognosis.24
Another candidate as a prognostic factor for RCC patients,
which deserves much attention, is IL-6. IL-6 is a pleiotropic
cytokine with a wide range of activity, evident especially in the
immune, hematopoietic and nervous system. Miki et al. on the
basis of their research demonstrated that mRNA  expression
of IL-6, IL-6 secretive activity of tumor tissues and anti-IL-6
antibodies inhibiting growth of the tumor can be observed
in freshly isolated tissues of RCC.25 Other research by Take-
nawa et al. shows that both primary RCC and RCC cell lines
express mRNA  of IL-6 and IL-6 receptor and that patients with
increased expression have greater incidence of metastases to
lymph nodes and an increased level of CRP.26 There are many
reports proving the role of IL-6 as an autocrine growth factorfound that 48% of RCC patients had a considerably higher IL-6
level that correlated with an increased concentration of CRP.27
Tsukamoto et al. demonstrated that an increased level of IL-
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6 occurred in 25% of patients with RCC, while Hamao et al.
observed an increase in IL-6 in 53% of cases.28,29 In the lit-
erature, there are also studies on the role of CRP assessed
after nephrectomy in patients with locally advanced RCC.
Johnson et al. of the Emory University in Atlanta (USA) moni-
tored CRP concentration before nephrectomy due to clear-cell
renal cell carcinoma and one year after the surgery on a
group of 110 patients (T1-3N0M0). The multifactorial anal-
ysis revealed a statistically signiﬁcant relationship between
postoperative CRP level, T-stage and recurrence-free survival
and OS (p < 0.001). The researchers demonstrated that postop-
erative CRP level can facilitate identiﬁcation of patients with
a high risk of progression more  than preoperative level of
the protein, which will allow to propose a complementary
therapy with anti-angiogenic drugs.30 A study by Kamem-
oto on patients with clear-cell renal cell carcinoma (stage
T1–2,N0M0) showed a normal level of IL-6 in blood serum.
The concentration of serum IL-6 was higher in patients with
advanced RCC (T3N0M0) and correlated with an increased CRP
level.31
The problem of identiﬁcation of prognostic factors in RCC,
raised in many  studies, seems to be of great importance. The
ongoing research conducted in numerous scientiﬁc centers,
allow clinicians to determine more  and more  precisely the
most signiﬁcant prognostic factors that inﬂuence the choice
of therapy and ability to determine further prognostication.
Our study is an attempt at emphasizing and presenting the
role of the most important parameters that seem to play
a role in prognostication in patients with clear-cell renal
cell carcinoma. So, the conclusion we drew on the basis
of the research conducted is that an increased preopera-
tive levels of CRP and IL-6 are negative prognostic factors
for OS and CSS in patients subjected to radical nephrec-
tomy due to RCC. On the other hand, a decrease in the
level of IL-6 and CRP in peripheral blood before nephrectomy
due to locally advanced RCC may be a valuable diagnostic
factor in later qualiﬁcation of patients for complementary
therapy.
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